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Iron is indispensable for red blood cell production, bacterial defence, and cellular respiration1; however, iron excess is cytotoxic. Therefore, systemic iron levels are maintained in a 
narrow range to avoid iron deficiency and anaemia or iron over-
load that leads to multiorgan damage. Compared with other 
organs, bone is highly susceptible to changes in iron homeostasis. 
Bone mineral density is negatively associated with systemic iron 
concentrations2, and patients suffering from hereditary haemo-
chromatosis, a disorder characterized by iron overload, develop 
premature osteoporosis3. Despite these observations, the relation-
ship between iron homeostasis and bone turnover remains largely 
unexplored.
Systemic iron concentrations are maintained by balancing 
dietary iron absorption and iron recycling from the reticuloen-
dothelial system1. Hepcidin is a hepatic peptide hormone and key 
regulator of iron homeostasis4. By binding to ferroportin, an iron 
exporter, hepcidin causes the internalization and degradation of fer-
roportin, thereby limiting iron export in circulation. Dysregulation 
of this mechanism leads to iron overload. Accordingly, mutations 
in the gene encoding hepcidin or hepcidin-regulating genes cause 
hereditary haemochromatosis5.
Tfr2 is a key regulator of hepcidin. Similar to humans, mice with 
global or liver-specific deletion of Tfr2 accumulate iron in the liver6–9. 
Tfr2 is proposed to control iron homeostasis by regulating hepci-
din expression and has two isoforms: Tfr2α , which represents the 
full-length protein and regulates iron homeostasis in the liver; and 
Tfr2β , which lacks the intracellular and transmembrane domains 
and plays an important role in iron efflux in the spleen8. To date, 
the mechanisms by which Tfr2 senses and regulates systemic iron 
concentrations remain incompletely understood. However, holo-
transferrin (holo-Tf) can bind Tfr2 and prolong its half-life10. Thus, 
Tfr2 has been postulated to sense circulating iron and activate hep-
cidin in response to elevated transferrin saturation.
Tfr2-deficient hepatocytes have reduced BMP and p38MAPK/
ERK signaling11–13, implicating these pathways in its signal transduc-
tion. Although BMP signalling is mostly known for its critical role 
in bone development and postnatal bone homeostasis14, it has also 
emerged as an important regulator of iron homeostasis. Deficiency 
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of several components of the BMP pathway (Bmpr1a, Bmpr2, Acvr1, 
Acvr2a, Smad4, Bmp2, Bmp6) or their pharmacological inhibition 
results in iron overload15–20. Moreover, hemojuvelin, another regula-
tor of hepcidin expression, has been identified as a hepatic BMP 
co-receptor16, further linking BMP signalling to iron homeostasis. 
Importantly, activating mutations in one of the BMP receptors that 
controls iron homeostasis, ACVR1, cause a rare disorder in humans, 
fibrodysplasia ossificans progressiva (FOP), which is characterized 
by excessive heterotopic ossification21. Thus, balancing BMP signal-
ling is necessary to maintain bone and iron homeostasis in a physi-
ological range.
Recent evidence indicates that Tfr2 is not restricted to the 
liver, but is also expressed in erythroid progenitors to ensure their 
proper differentiation8,22,23. As BMP signalling has a critical role in 
the skeleton14,24, we hypothesized that Tfr2 may possess additional 
extrahepatic functions and regulate bone homeostasis. Here, 
we demonstrate that Tfr2 is a novel negative regulator of bone 
turnover. By binding BMP ligands, Tfr2 activates p38MAPK 
signalling in osteoblasts to induce expression of the Wnt inhibitor 
sclerostin and limit bone formation. Finally, by taking advantage 
of the BMP-binding property of the Tfr2 extracellular domain, 
we show that this protein fragment effectively inhibits hetero-
topic ossification in two preclinical models, suggesting that it 
may also be efficacious in treating disorders of pathological 
bone formation.
Results
Tfr2 deficiency leads to high bone mass. To investigate whether 
the iron-sensing receptor Tfr2 regulates bone homeostasis, we 
studied Tfr2−/− mice, which are iron overloaded. Consistent with 
previous reports8,25, transferrin saturation, serum iron and ferri-
tin concentrations, and iron content in the liver were increased in 
Tfr2–/– mice compared with wild-type (WT) mice (Supplementary 
Fig. 1a–d). Additionally, atomic absorptiometry revealed a higher 
iron content in the cortical bone of Tfr2–/– mice (Supplementary Fig. 
1e). As iron overload is associated with bone loss3, we expected a 
decrease in bone volume in Tfr2–/– mice. However, in contrast to the 
low bone mass phenotype of mice with diet-induced iron overload, 
and in different mouse models of haemochromatosis, including 
Hfe–/– mice26 and FpnC326S mutant mice27 (Supplementary Fig. 2a–c), 
Tfr2–/– mice displayed a 1.5- to 3-fold increase in trabecular bone 
volume in the femur and vertebrae and a 1.5-fold increase in corti-
cal bone density compared with WT controls (Fig. 1a,b). High bone 
mass was independent of sex and declined with age (Supplementary 
Fig. 3a,b). At a structural level, Tfr2–/– vertebrae had increased 
trabecular number (Tb.N) and thickness (Tb.Th) and decreased 
separation (Tb.Sp) (Fig. 1c–e). Furthermore, Tfr2–/– mice had 
increased trabecular bone micromineralization density (Supple-
mentary Fig. 3c), which, together with the increased bone volume, 
enhances bone strength (Fig. 1f).
We performed dynamic and static histomorphometry to deter-
mine whether the high bone mass phenotype was a consequence 
of increased bone formation or decreased bone resorption. Tfr2 
deficiency resulted in an increase in both osteoblast and osteoclast 
parameters. The bone formation rate and the serum concentra-
tion of the bone formation marker pro-collagen type I N-terminal 
peptide (P1NP) were elevated more than two-fold in Tfr2–/– mice, 
and the number of osteoclasts and the serum concentration of 
the bone resorption marker C-terminal telopeptide of type I col-
lagen (CTX) were similarly increased (Fig. 1g–l). The high bone 
turnover was present in both male and female mice, at all ages 
studied (Supplementary Fig. 3d,e). Interestingly, Tfr2–/– mice were 
not protected from ovariectomy-induced bone loss, but lost even 
more bone than WT mice (Fig. 1m). Taken together, these data 
demonstrate that Tfr2 controls not only iron homeostasis, but also 
bone turnover.
High bone mass in Tfr2-deficient mice is independent of hepatic 
iron status or Tfr2 expression in the liver. As Tfr2–/– mice are iron 
overloaded and have high bone mass (though iron overload is com-
monly associated with decreased bone mass3,28), we investigated 
whether abnormal iron metabolism contributes to the skeletal phe-
notype in Tfr2–/– mice. Thus, Tfr2–/– mice were given an iron-free 
diet for 8 weeks from weaning or were treated with the iron chelator 
deferoxamine for 3 weeks from 10 weeks of age. Despite successful 
iron depletion by both regimens, bone mass remained elevated in 
Tfr2–/– mice (Fig. 2a–d), thus indicating that the high bone mass 
phenotype in Tfr2–/– mice is independent of the hepatic iron status.
To corroborate these findings, we studied two distinct Tfr2-
mutant mouse models, which globally lack Tfr2β but have con-
trasting Tfr2α expression that results in divergent abnormalities 
of iron homeostasis8: Tfr2 knock-in (KI) mice, which globally lack 
Tfr2β but have normal Tfr2α and, thus, normal iron parameters; 
and hepatocyte-specific Tfr2 knock-out (LCKO) mice, which glob-
ally lack Tfr2β and have Tfr2α deficiency that is restricted to the 
liver, but are severely iron overloaded. Both mutant mouse models 
showed comparable bone volume fractions compared with controls 
(Fig. 2e,f), thus indicating that neither Tfr2β nor hepatic Tfr2α play 
a role in the control of bone homeostasis.
Tfr2 deficiency in osteoblasts drives the high bone mass pheno-
type. To explore whether Tfr2 regulates bone mass directly via its 
expression in skeletal cells, we determined the expression pattern of 
Tfr2α and Tfr2β in various mouse tissues. As expected, Tfr2α was 
predominantly expressed in the liver, followed by expression in fem-
oral cortical bone (Supplementary Fig. 4a). Tfr2β mRNA expression 
was also detected in femoral cortical bone, but at a much lower level 
(CT (threshold cycle) value, spleen (positive control): 26; CT value, 
bone: 32). Using an antibody that binds to the extracellular domain 
of Tfr2, and thus detects both Tfr2α and Tfr2β isoforms, we con-
firmed expression of Tfr2 in vertebral bone sections, showing Tfr2-
positive osteoclasts, osteoblasts, and osteocytes (Fig. 3a,d). Staining 
of bone sections from Tfr2–/– mice showed no nonspecific binding of 
the Tfr2 antibody (Supplementary Fig. 3b). Osteoclasts and osteo-
blasts differentiated from bone marrow of WT mice both expressed 
Tfr2α and Tfr2β mRNA transcripts ex vivo, but expression of Tfr2β 
was very low in each cell type (data for Tfr2β not shown). Tfr2α was 
readily detectable in osteoclasts and osteoblasts, with peak levels of 
expression in mature osteoclasts (day 7 of 7) and in immature osteo-
blasts (day 7 of 21) (Fig. 3b,e). Immunocytochemistry confirmed 
Tfr2 expression in osteoclasts and osterix-expressing osteoblasts 
that were differentiated ex vivo (Fig. 3c,f). Subcellular fractioning of 
osteoblasts further localized the majority of Tfr2 to the membrane 
fraction (Fig. 3g). A low signal was also detected in the cytoplasm.
To determine if Tfr2 in osteoclasts or in osteoblasts regulates 
bone turnover, we performed reciprocal bone marrow transplanta-
tions. In WT and Tfr2–/– mice, bone marrow transplantation had no 
effect on vertebral or femoral bone volume irrespective of donor 
genotype (Fig. 3h), suggesting that Tfr2 deficiency in the haema-
topoietic compartment is not responsible for the high bone mass 
phenotype in Tfr2–/– mice. Consistent with these findings, specific 
deletion of Tfr2 in the myeloid lineage (Lysm-cre) and in mature 
osteoclasts (Ctsk-cre) did not affect bone volume at the spine 
(Fig. 3i). Femoral bone volume decreased in Tfr2f/f;Lysm-cre mice, 
but not in Tfr2f/f;Ctsk-cre mice (Supplementary Fig. 5a). By contrast, 
deletion of Tfr2 in osteoblast progenitors, in which Tfr2 expression 
is highest, increased bone mass at the femur and spine (Fig. 3j), 
increased trabecular number, and decreased trabecular separation 
(Fig. 3k). Bone formation was increased in Tfr2f/f;Osx-cre mice (Tfr2 
deletion in osteoblast precursors), as reflected by higher serum 
P1NP levels (Fig. 3l) and a higher bone formation rate (Fig. 3m). 
Finally, deletion of Tfr2 in osteoblasts did not change osteoclast 
numbers, but tended to increase serum levels of CTX (Fig. 3n,o). 
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Consistent with data published from Tfr2f/f;Lysm-cre mice29, Tfr2f/f; 
Ctsk-cre and Tfr2f/f;Osx-cre mice showed a normal liver iron con-
tent (Supplementary Fig. 5b,c). Taken together, these data indicate 
that Tfr2 predominantly in osteoblasts regulates bone formation but 
does not contribute to systemic iron homeostasis.
Tfr2 deficiency in osteoblasts attenuates BMP-MAPK signalling 
and results in decreased expression of Wnt inhibitors. Because 
data indicated a direct role for Tfr2 in osteoblasts, we performed a 
genome-wide RNA sequencing analysis using primary osteoblasts 
from WT and Tfr2–/– mice to identify signalling pathways affected 
by deletion of Tfr2. A total of 5,841 differentially expressed genes 
were identified (Supplementary Data Set 1). We performed gene 
ontology analysis to determine the biological processes affected 
by Tfr2 deficiency (complete list in Supplementary Table 1). Genes 
upregulated in Tfr2–/– osteoblasts were involved in negative regula-
tion of protein secretion and muscle systems. By contrast, genes 
involved in ossification, extracellular matrix organization, nega-
tive regulation of Wnt signalling, and Smad phosphorylation were 
downregulated in Tfr2–/– osteoblasts (Supplementary Fig. 6a). These 
data are consistent with those of molecular function and cellular 
component analyses, which revealed under-representation of genes 
involved in glycosaminoglycan and heparin binding, as well as BMP 
receptor binding and proteinaceous extracellular matrix and colla-
gen formation (Supplementary Fig. 6a). Gene set enrichment analy-
sis further demonstrated under-representation of genes involved 
in late osteoblastic differentiation and Wnt signalling, the latter of 
which is associated with marked suppression of the Wnt inhibitor 
Dickkopf-1 (Dkk1) (Supplementary Fig. 6b,c; complete list of sig-
nificantly enriched gene sets is in Supplementary Table 2).
Dkk1 and Sost (encoding the Wnt inhibitor sclerostin) were 
among the 25 most downregulated genes in Tfr2–/– osteoblasts 
ex vivo (Fig. 4a). Reduced expression of the two Wnt inhibitors 
was verified via quantitative PCR (qPCR) and is consistent with 
increased expression of the Wnt target genes Axin2, Lef1, and Cd44 
(Supplementary Fig. 6c). Dkk1 and Sost mRNA levels were also 
downregulated in osteoblasts obtained from Tfr2f/f;Osx-cre mice 
(Fig. 4b). Furthermore, expression of the osteocyte-associated genes 
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Fig. 1 | Tfr2 deficiency results in high bone mass. a–l, The bones and serum bone turnover markers of 10-week-old male WT or Tfr2–/– mice were analysed 
using µ CT, histology, and ELISAs. a, Three-dimensional reconstruction and quantitation of the bone volume per total volume (BV/TV) of the distal femur 
and the fourth vertebral body of WT and Tfr2–/– mice. Femur, n =  5 mice per group; vertebral body, n =  4 mice per group. b, Cortical bone mineral density 
(BMD) at the femoral midshaft. n =  4 mice per group. c–e, Quantitation of vertebral trabecular number (Tb.N) (c), trabecular thickness (Tb.Th) (d), and 
trabecular separation (Tb.Sp) (e). n =  4 mice per group. f, Maximum force at the femoral shaft assessed by three-point-bending. (WT, n =  6; Tfr2–/–, n =  7). 
g, Representative histological sections from the third vertebral body of WT and Tfr2–/– mice showing calcein double staining (green). Scale bar, 100 µ 
m. These experiments were repeated four times with similar results. h, Quantification of the bone formation rate per bone surface (BFR/BS). WT, n =  4; 
Tfr2–/–, n =  6. i, Quantification of serum P1NP as a marker of bone formation. WT, n =  4; Tfr2–/–, n =  5. j, Representative histological tartrate-resistant acid 
phosphatase sections from the fourth vertebral body of WT and Tfr2–/– mice showing osteoclasts stained in pink. Scale bar, 100 µ m. These examinations 
were performed four times with similar results. k, Quantification of the number of osteoclasts per bone perimeter (N.Oc/B.Pm). WT, n =  4; Tfr2–/–, n =  6.  
l, Quantification of serum CTX as a marker of bone resorption. WT, n =  4; Tfr2–/–, n =  5. a–f, h,i,k,l, A two-tailed t test was used for statistical analysis. 
m, µ CT analysis of femoral bone of 12-week-old sham-operated (SHAM) or ovariectomized (OVX) WT and Tfr2–/– mice. WT SHAM, n =  6; WT OVX, 
n =  9; Tfr2–/– SHAM, n =  5; Tfr2–/– OVX, n =  10. Two-way ANOVA with Bonferroni post hoc test was used for statistical analysis. Data in all subpanels are 
presented as mean ±  s.d. *P <  0.05, **P <  0.01, ***P <  0.001.
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Phex and Dmp1 decreased (Supplementary Fig. 6c). Importantly, 
impaired expression of osteocytic markers was not caused by reduced 
osteocyte number in Tfr2–/– bone (WT, 8.73 ± 2.74 versus Tfr2–/–, 
9.77 ± 0.85 osteocytes per bone volume fraction). Low concentra-
tions of sclerostin and Dkk1 were detected in the serum of Tfr2–/– 
mice (Fig. 4c), along with a greater proportion of osteoblasts and 
osteocytes with high expression of β -catenin and axin-2 (Fig. 4d). 
Finally, western blot analysis of β -catenin showed increased Wnt 
signalling in Tfr2–/– osteoblasts differentiated for 7 d (Fig. 4e).
Results from deep-sequencing analysis suggested decreased BMP 
signalling in Tfr2–/– osteoblasts, and recent studies have indicated 
that Sost and Dkk1 are downstream targets of BMP signalling30,31. 
Thus, we analysed BMP target genes as well as the basal canoni-
cal (Smad) and non-canonical (MAPK) BMP signalling pathways in 
Tfr2–/– and WT osteoblasts. Smad6 and Id1 were significantly down-
regulated in Tfr2–/– osteoblasts, whereas Id2 expression was simi-
lar between WT and Tfr2–/– osteoblasts (Supplementary Fig. 6c). 
Smad1, Smad5, and Smad8 phosphorylation as well as ERK and p38 
activation were decreased in Tfr2–/– osteoblasts compared with WT 
osteoblasts (Fig. 4e). Moreover, activation of BMP signalling after 
BMP-2 treatment demonstrated that Smad activation was delayed 
in Tfr2–/– osteoblasts, whereas activation of p38MAPK and ERK was 
persistently impaired (Fig. 4f,g). The reduced activation of nonca-
nonical BMP signalling in Tfr2–/– osteoblasts was not restricted to 
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Fig. 2 | High bone mass in Tfr2–/– mice is independent of iron overload and the hepatic function of Tfr2. a,c, Male WT and Tfr2–/– mice received a purified 
diet without iron (–Fe) starting from weaning until the age of 10 weeks. Control mice received a standard diet with 0.2 g iron/kg food (+ Fe). a, Liver iron 
content was determined on dried tissue using photometry (mean ±  s.d.; n =  10 mice per group). c, Bone volume/total volume (BV/TV) was assessed 
using µ CT (mean ±  s.d.; WT + Fe, n =  9; WT –Fe, Tfr2–/– + Fe, and Tfr2–/– –Fe, n =  8 per group). b,d, 10-week-old female WT and Tfr2–/– mice received daily 
intraperitoneal injections of 250 mg/kg deferoxamine (DFO) or PBS for 3 weeks. At 13 weeks of age, mice were euthanized to measure liver iron  
content (b) and BV/TV (d). (mean ±  s.d.; WT + Fe, n =  4; WT –Fe, n = 3; Tfr2–/– + Fe, n = 4, Tfr2–/– –Fe, n =  4). a–d, Two-way ANOVA with Bonferroni post 
hoc test was used for statistical analysis. e, Schematic representation of Tfr2-KI mice, which lack the Tfr2β isoform and BV/TV and liver iron content of 
10-week-old male Tfr2-KI mice and control mice (BV/TV, WT n =  11, KI n =  15; liver iron, WT n =  8, KI n =  7). f, Schematic representation of the Tfr2 setup 
of LCKO mice on a Tfr2-KI background and BV/TV and liver iron content of 10-week-old male LCKO and WT mice (n =  8 per group). e,f, A two-tailed t test 
was used for statistical analysis. All data are presented as mean ±  s.d. *P <  0.05, **P <  0.01, ***P <  0.001.
Fig. 3 | Deficiency of Tfr2 in osteogenic cells increases bone mass. a,d, Immunohistochemical analysis of Tfr2 on vertebral bone of WT mice. One 
representative image is shown out of three experiments. Arrows indicate Tfr2 expression in multinucleated osteoclasts and osteoblasts/osteocytes 
(osteoblasts, black arrows; osteocytes, orange arrows). Scale bar, 20 µ m. b,e, Tfr2α mRNA expression during osteoclast (b) and osteoblast (e) 
differentiation of WT cells (n =  4). c,f, Immunofluorescence staining for Tfr2 in mature osteoclasts (c) and immature osteoblasts (f). Scale bar, 20 µ m. 
This staining was repeated twice with similar results. g, Subcellular fractioning of day 7 osteoblast protein lysates from WT mice. One representative 
blot is shown out of three experiments. CP, cytoplasm; M, membrane; Nuc, nuclear fraction; Cx-43, connexin-43. h, Bone marrow was transplanted from 
12-week-old male WT or Tfr2–/– mice (donor) into lethally irradiated 9-week-old male WT and Tfr2–/– recipient (recip) mice. After 16 weeks, the BV/TV was 
measured using µ CT (L4: WT–WT, n =  11; Tfr2–/––WT, n =  11; Tfr2–/––Tfr2–/–, n =  7; WT–Tfr2–/–, n =  9; femur: WT–WT, n =  12; Tfr2–/––WT, n =  10; Tfr2–/––Tfr2–/–, 
n =  8; WT–Tfr2–/–, n =  10). Two-way ANOVA with Bonferroni post hoc test was used for statistical analysis. i, BV/TV of the fourth lumbar vertebrae of 
10-week-old male cre-positive (Cre+ ) and cre-negative (Cre–) Tfr2f/f;Lysm-cre and Tfr2f/f;Ctsk-cre mice (Tfr2f/f;Lysm-cre: Cre–, n =  16; Cre+ , n =  9; Tfr2f/f; 
Ctsk-Cre: Cre–, n =  8; Cre+ , n =  12). j–o, Bone analysis of 10-week-old male cre-positive and cre-negative littermate control Tfr2f/f;Osx-Cre mice. j, BV/TV 
(L4: Cre–, n =  18, Cre+ , n =  12; femur: Cre–, n =  18, Cre+ , n =  13). k, Trabecular number (Tb.N) and trabecular separation (Tb.Sp) (Tb.N., Cre– n =  18, Cre+ , 
 n =  13; Tb.Sp., Cre– n =  19, Cre+ , n =  12). l, Serum levels of P1NP (n =  6 per group). m, Mineralizing surface per bone surface (MS/BS), mineral apposition 
rate (MAR), and bone formation rate per bone surface (BFR/BS) determined at the lumbar spine (MS/BS: Cre–, n =  11; Cre+ , n =  10; MAR: Cre– n =  9, Cre+ , 
 n =  6; BFR: Cre– n =  10; Cre+ , n =  6). n, Osteoclast surface per bone surface (Oc.S/BS) analysed at the lumbar spine (Cre–, n =  7, Cre+ , n =  6). o,  
Serum CTX levels (n =  6 per group). i–o, A two-tailed Student’s t test was used for statistical analysis. All data are presented as mean ±  s.d. *P <  0.05, 
**P <  0.01, ***P <  0.001.
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BMP-2 treatment, but was also observed after BMP-4 treatment and, 
to a lesser extent, BMP-6 stimulation (Fig. 4h and Supplementary 
Fig. 6d). Overall, Tfr2 deficiency in osteoblasts results in impaired 
BMP signalling and increased activation of the Wnt pathway.
Reactivation of MAPK signalling or overexpression of sclerostin 
rescues high bone mass in Tfr2 deficiency. We next investigated 
the mechanisms underlying the Tfr2-mediated regulation of Sost 
expression, as this may be a major driver of the Tfr2-dependent 
effects on bone. Using Tfr2–/– osteoblasts in vitro, we confirmed 
the lack of induction of Sost expression after stimulation with 
BMP-2, BMP-4, and BMP-7 (Fig. 5a). Conversely, overexpression 
of Tfr2 in WT and Tfr2–/– osteoblasts markedly increased Sost, 
particularly after stimulation with BMP-2 (Fig. 5b and Supplemen-
tary Fig. 7a). To test the impact of sclerostin in producing the 
high bone mass phenotype in Tfr2–/– mice, we crossed Tfr2–/– mice 
with mice overexpressing human SOST in late osteoblasts and 
osteocytes (under the Dmp1 8-kb promoter). Overexpression of 
SOST significantly reduced the vertebral trabecular bone volume 
in Tfr2–/– mice (Fig. 5c) and normalized the bone formation rate 
(Fig. 5d). The osteoclast-covered bone surface was higher in 
Tfr2–/– mice and in WT mice overexpressing SOST in osteoblasts 
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and osteocytes compared with mice with normal Sost expression 
(Supplementary Fig. 7b).
Previous studies have indicated that BMPs stimulate Sost expres-
sion via the BMP-Smad and BMP-MAPK pathways30,31. Because 
pERK and pp38 were most markedly reduced in Tfr2–/– osteoblasts, 
and neither Smad1 nor Smad4 overexpression in Tfr2–/– osteoblasts 
restored Sost mRNA levels (Supplementary Fig. 7c–f), we reactivated 
the MAPK pathways using anisomycin to rescue Sost expression. 
Treatment with anisomycin induced ERK and p38 phosphorylation 
(Supplementary Fig. 7g) and increased Sost mRNA expression in 
Tfr2–/– and WT osteoblasts: 19-fold in Tfr2–/– osteoblasts and 14-fold 
in WT osteoblasts at 100 nM anisomycin (Fig. 5e). Similarly, treat-
ment of Tfr2–/– mice with anisomycin for 3 weeks increased serum 
levels of sclerostin (Fig. 5f), reduced osteoblast numbers (Fig. 5g), 
and decreased bone volume back to WT levels (Fig. 5h). Osteoclast 
numbers were not altered by anisomycin treatment (Supplementary 
Fig. 7h). Finally, we investigated which specific MAPK pathway, 
ERK or p38, regulates Sost expression. Overexpression of Mapk14 
(encoding p38α ), but not Mapk1 (encoding ERK2), restored 
reduced Sost levels in Tfr2–/– osteoblasts (Fig. 5i,j). Thus, Tfr2 con-
trols bone mass by inducing Sost expression via the p38MAPK 
signalling pathway.
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Tfr2 is a novel interaction partner of BMPs. Finally, we asked how 
Tfr2 can lead to impaired BMP-MAPK signal transduction in osteo-
blasts and thus explored whether Tfr2 can act as a BMP receptor. We 
generated a protein fragment containing the extracellular domain 
of Tfr2 (Tfr2-ECD), confirmed using SDS–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and western blot (Supplementary Fig. 8a), 
and performed surface plasmon resonance (SPR) analysis. Tfr2-
ECD immobilized on sensor-chip-bound BMP-2, BMP-4, BMP-6, 
and BMP-7 more avidly than holo-Tf (Fig. 6a and Supplementary 
Fig. 8b), the only known Tfr2 ligand10. BMP-2, BMP-4, and BMP-6 
also bound Tfr2-ECD at high salt concentrations, which were 
used to reduce nonspecific binding, although with a lower binding 
response (Supplementary Fig. 8c). Tfr2-BMP binding was further 
verified via an inverse approach using Tfr2-ECD as an analyte and 
BMP-2 or BMP-4 immobilized on the sensor chip (Supplementary 
Fig. 8d,e). Using this approach, we determined Kd values for Tfr2–
BMP-2 (488.0 ± 37.0 nM) and Tfr2–BMP-4 (409.1 ± 39.0 nM) 
binding via steady-state analysis. Holo-Tf bound to Tfr2 at micro-
molar concentrations, suggesting a Kd value in the micromolar 
range (Supplementary Fig. 8f). Holo-Tf and BMP-2 did not com-
pete for binding to Tfr2, as the sequential injection of either BMP-2 
then holo-Tf or holo-Tf then BMP-2 did not change the initial bind-
ing response (Supplementary Fig. 8g,h). Interestingly, concomitant 
injection of BMP-2 and holo-Tf led to a much stronger binding 
response to Tfr2 than either analyte alone (Fig. 6b). As BMPs nor-
mally signal through a receptor complex consisting of the type I and 
type II BMP receptors, we tested whether BMP receptors (BMPRs) 
bind to Tfr2-ECD. Both BMPR-IA and BMPR-II had binding 
responses weaker than those of BMPs (Fig. 6a and Supplementary 
Fig. 8i). The physical interaction of Tfr2 and BMPR-IA was further 
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investigated using a cell system in which they were both overex-
pressed. Their interaction was confirmed by coimmunoprecipita-
tion and was not affected by the presence of BMP-2 (Supplementary 
Fig. 8j). BMP-2 binding to the Tfr2-ECD was further verified using 
a competitive sandwich ELISA with BMPR-IA as a control (Fig. 
6c). Additional SPR experiments revealed that BMPR-IA competes 
with Tfr2 for BMP-2 binding, as adding increasing concentrations 
of BMPR-IA reduced binding of BMP-2 to Tfr2-ECD (Fig. 6d). Of 
note, high nanomolar concentrations of BMPR-IA were required for 
competing with Tfr2–BMP-2.
We validated the BMP ligand binding property of Tfr2-ECD 
in vivo using a heterotopic ossification model. In this model, BMP-2 
is injected into the anterior tibialis muscle of mice, which leads 
to muscular ossification32. Whereas injection of BMP-2 alone led 
to heterotopic ossification of the muscle in WT mice, the addi-
tion of Tfr2-ECD completely abrogated this effect (Fig. 6e and 
Supplementary Fig. 9a,b), suggesting that Tfr2 binds BMP-2 and 
prevents it from binding to its cognate BMPR. Similar experiments 
in Tfr2–/– mice demonstrated increased heterotopic ossification 
after BMP-2 injection compared with WT mice, which was sig-
nificantly inhibited by co-application of Tfr2-ECD (Fig. 6e and 
Supplementary Fig. 9a,b). Thus, in addition to confirming func-
tional BMP-binding activity of the Tfr2-ECD in vivo, these data 
emphasise the role of Tfr2 as a negative regulator of ossification in a 
BMP-dependent context.
Tfr2-ECD potently inhibits heterotopic ossification in two dis-
tinct preclinical models. Due to the robust effect of the Tfr2-
ECD in diminishing BMP-2-induced heterotopic ossification, we 
compared Tfr2-ECD with palovarotene, a selective retinoic acid 
receptor-γ agonist that indirectly inhibits BMP signalling33 and is 
currently under clinical investigation for the treatment of FOP. We 
c
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heterotopic ossification (HO) model in 12-week-old female WT mice. HO after three weeks assessed using µ CT. Pal, palovarotene; Ibu, ibuprofene. n =  6 
per group; *P <  0.05, ***P <  0.001 vs. PBS control. f,g, One-way ANOVA was used for statistical analysis. All data are presented as mean ±  s.d. h,  
Scheme of the mode of action of the Tfr2-ECD in the treatment of HO. Left, HO is induced by overactive BMP signalling, leading to the induction  
of osteoblastic genes and bone formation. Right, Tfr2-ECD neutralizes BMPs, preventing them from activating BMP signalling. Thus, osteoblastic  
bone formation is inhibited.
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tested Tfr2-ECD as a single local treatment into the muscle and as 
a systemic treatment (intraperitoneal injections every other day). 
Both regimens reduced BMP-2-induced heterotopic ossification 
in WT mice after two weeks, with similar efficacy to that of daily 
palovarotene administration (Fig. 6f). Investigation of the chon-
drogenic phase of heterotopic ossification at day 8 in WT mice 
revealed that both systemic Tfr2-ECD and palovarotene treat-
ment suppressed the number of chondrocytes and production of 
cartilage (Supplementary Fig. 9c,d). No adverse effects of systemic 
Tfr2-ECD treatment were observed on blood counts, iron param-
eters, bone homeostasis or the gross morphology of internal organs 
(Supplementary Table 3). Finally, we tested both compounds in a 
model of trauma-potentiated heterotopic ossification, a frequent 
complication after trauma, blast injuries, or hip replacement surger-
ies. A single dose of Tfr2-ECD inhibited new bone formation in the 
muscle, comparable to palovarotene (Fig. 6g). Daily treatment with 
ibuprofen, a frequent treatment of heterotopic ossification after hip 
surgeries34, did not prevent trauma-induced heterotopic ossification 
(Fig. 6g). These data indicate that Tfr2-ECD is a potent inhibitor of 
heterotopic ossification and represents a potential new therapeutic 
strategy for treating disorders of excessive bone formation.
Discussion
Using a series of genetically modified mice and in vitro analyses, we 
identified a new role for Tfr2 as a modulator of BMP and Wnt signal-
ling in osteoblasts. Tfr2 interacts with BMP ligands and receptors, 
activates p38MAPK signalling, and induces expression of the Wnt 
inhibitor Sost, blocking canonical Wnt signalling and thereby limit-
ing bone formation and bone mass accrual (Fig. 5k). Furthermore, 
exploiting the BMP-binding property of the Tfr2-ECD in the form 
of a decoy receptor shows promise as a novel therapeutic strategy 
to prevent heterotopic ossification (Fig. 6h), which is of particular 
interest, as there are currently no specific treatments for congenital 
or trauma-induced heterotopic ossification.
Aside from its well-known function in the regulation of systemic 
iron levels6–9, Tfr2 also ensures proper erythropoiesis8,22,23. Our 
study has now identified a novel extrahepatic role of Tfr2, control 
of bone mass via direct action in osteoblasts, though minor effects 
in myeloid cells, including early osteoclasts, cannot be excluded. 
This function appears to be a unique property of Tfr2 among the 
other iron-regulating proteins, as all other investigated mouse mod-
els of haemochromatosis display low bone mass. Accordingly, other 
studies have shown low bone mass in patients with HFE-dependent 
haemochromatosis3 and in Hfe- and hepcidin-deficient mice35,36. In 
both cases, suppressed bone formation was proposed as the main 
underlying mechanism of low bone mass35,37. However, as both 
Hfe- and hepcidin-deficient mice are iron overloaded, it is unclear 
whether the low bone mass is an indirect result of the negative 
effects of iron overload or whether Hfe and hepcidin act directly in 
bone cells. Importantly, the high bone mass in Tfr2-deficient mice 
was independent of the iron status and the hepatic function of Tfr2, 
indicating Tfr2 has distinct roles in osteoblasts (control of matrix 
production) and hepatocytes (regulation of hepcidin expression 
and systemic iron homeostasis).
Even though Tfr2 has been known as a regulator of iron homeo-
stasis for over 15 years, its mechanisms of action have remained 
elusive. Decreased levels of Smad1, Smad5, and Smad8 and MAPK/
ERK signalling in Tfr2-deficient hepatocytes suggested that BMP 
signalling may be involved11,13,38, but it remained unclear how Tfr2 
activates BMP signalling. Previous studies in hepatocytes have 
suggested that Tfr2 forms a ternary complex with Hfe and hemo-
juvelin to activate hepcidin expression12. Our data, however, pro-
vide in vitro and in vivo evidence that demonstrates that Tfr2 
can bind BMPs directly and activate downstream signalling. 
Binding of BMP-2 to Tfr2 was more than tenfold higher than that of 
holo-Tf, the only known ligand for Tfr2 (ref. 10). Compared with 
BMP–BMPR interactions39,40, BMP–Tfr2 binding affinity was mark-
edly lower, suggesting that Tfr2 may act to fine-tune BMP signal-
ling. As our studies also showed a direct interaction of Tfr2 with 
BMPRs, it remains to be investigated whether Tfr2 binds BMPs 
alone or within a multireceptor complex with BMPRs and/or other 
BMP co-receptors. Despite these first indications of Tfr2 being a 
BMP (co)-receptor, additional experiments will be required to 
define accurate binding affinities that account for stoichiometry, the 
possibility of receptor dimerization or oligomerization, and Tfr2-
ECD purity. Interestingly, the combination of holo-Tf and BMP-2 
bound much more avidly to Tfr2 than either holo-Tf or BMP-2 
alone, suggesting that holo-Tf may exhibit considerable Tfr2 bind-
ing only in the presence of BMPs. This may be of particular impor-
tance, as hepatic endothelial cells have been identified as the main 
producers of BMP-2 and BMP-6 that act locally on hepatocytes to 
control hepcidin expression and iron homeostasis41,42. While hemo-
juvelin has been known to transmit the signal of BMP-6 to modulate 
hepcidin expression, BMP-6 can still induce hepcidin expression in 
hemojuvelin knock-out mice43, suggesting that other receptors must 
be involved. Thus, the newly identified BMP-binding properties of 
Tfr2 may represent the missing link in the regulation of hepcidin 
via BMPs.
Our study further showed that BMP downstream signalling, 
in particular the BMP-p38MAPK pathway, is impaired in Tfr2–/– 
osteoblasts, resulting in reduced expression of the canonical Wnt 
inhibitors Dkk1 and Sost, which are both potent negative regulators 
of bone formation44–46. Recent work has shown that BMP-2 stim-
ulates expression of Dkk1 and Sost by activating BMP-dependent 
Smad signalling and, in the case of Dkk1, through MAPK signalling 
via ERK and p38 (refs 30,47). More-recent studies, including our own, 
show that Sost expression is also induced by p38MAPK signalling in 
osteoblasts30,48. Accordingly, anisomycin treatment, which activates 
all three MAPKs49, rescued Sost expression and restored bone mass 
in Tfr2–/– mice. Similar to the phenotype of Tfr2–/– mice and coun-
terintuitive to the supportive role of BMP signalling in osteoblastic 
bone formation, targeted disruption of Bmpr1a or Acvr1 in osteo-
blasts impairs expression of Sost and results in high bone mass47,50. 
Additionally, treatment of Bmpr1a-deficient calvaria with recombi-
nant sclerostin ex vivo restored normal bone morphology47, similarly 
to overexpression of SOST in Tfr2–/– mice reducing bone volume to 
WT levels. However, Tfr2-deficient mice do not fully phenocopy 
the skeletal phenotype of Bmpr1a- or Sost-deficient mice. With 
osteoblast- and osteocyte-specific knock-out strains, deletion of 
Tfr2, Sost, and Bmpr1a leads to high bone mass. However, whereas 
Bmpr1a-conditional knock-out mice have low bone turnover30,47,51, 
Tfr2-conditional knock-out mice have a high bone formation rate 
and normal osteoclast parameters, and Sost-conditional knock-
out mice have a high bone formation rate52. Osteoclast parameters 
have not been reported in Sost-conditional knock-out mice, but 
are normal in Sost–/– mice44. Whereas an increase in bone forma-
tion appears to be the predominant mechanism of high bone mass 
in Tfr2- and Sost-conditional knock-out mice, the main driver of 
high bone mass in Bmpr1a-conditional knock-out mice appears 
to be reduced osteoclastogenesis due to a low RANKL-to-OPG 
ratio in osteoblasts30,47. This mechanism was reported to be inde-
pendent of Wnt signalling, as overexpression of Sost did not res-
cue the osteoclast phenotype in Bmpr1a-conditional knock-out 
mice47. By contrast, Tfr2–/– mice have elevated osteoclast numbers 
and an increased RANKL-to-OPG ratio (WT, 0.225 ± 0.046; Tfr2–/–, 
0.696 ± 0.120; n = 4, P = 0.0003), but, similar to Bmpr1a-conditional 
knock-out mice, this phenotype was not rescued by Sost overex-
pression. Interestingly, deficiency of Bmpr2 in osteoblasts results in 
high bone mass accompanied by a high bone formation rate and 
normal bone resorption53, suggesting that Tfr2 shares more similar-
ities with Bmpr2 than Bmpr1a. Finally, Bmpr1a-conditional knock-
out mice have disorganised bone matrix, leading to reduced bone 
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strength54,55. This finding is in contrast with Tfr2–/– and Sost–/– mice, 
which both have normal bone matrix organization and increased 
bone strength44. Despite similarities that propose Tfr2 acts in a simi-
lar way or even in conjunction with BMPRs, additional pathways 
appear to mediate its effects on bone, independent of BMP signal-
ling. Thus, Tfr2 is clearly a critical regulator of Sost expression in 
osteoblasts and provides another link between BMP and Wnt sig-
nalling.
Finally, we show that the ability of the Tfr2-ECD to bind BMPs 
and act as a decoy receptor reduces heterotopic ossification in two 
distinct preclinical models. Heterotopic ossification is a serious and 
common medical complication after blast injuries, such as those 
found in soldiers and civilians, burn victims, and recipients of total 
hip endoprostheses. Up to 30% of patients undergoing hip replace-
ment surgery and 50% of severely wounded soldiers develop het-
erotopic ossification56,57. Extensive heterotopic ossification is also a 
hallmark of FOP, a rare human disease caused by an activating muta-
tion in the gene encoding a BMP type I receptor, ACVR1 (ref. 21). 
Since the identification of this mutation, BMP signalling has been 
implicated in the pathogenesis of heterotopic ossification. To date, 
therapeutic options for FOP and trauma-induced heterotopic ossi-
fication are limited. Radiation and nonsteroidal antirheumatic 
drugs are frequently used to inhibit surgery-induced heterotopic 
ossification, with varying success34. In our study, ibuprofen did not 
significantly reduce heterotopic ossification. In FOP, glucocorti-
coids are used to reduce inflammation during flare-ups. However, 
they do not block progressive ossification. Rapamycin, anti-activin 
antibodies, and palovarotene have recently been shown to reduce 
heterotopic ossification in preclinical models of FOP via different 
mechanisms33,58–60. Palovarotene indirectly interferes with the BMP 
pathway and is currently the only drug under clinical investigation. 
Both local and systemic treatment with Tfr2-ECD inhibited het-
erotopic ossification to a similar extent as palovarotene. Systemic 
treatment with Tfr2-ECD did not show adverse effects on iron or 
bone metabolism within the 2-week treatment period, which is of 
relevance, as mice lacking Tfr2β, which has a similar structure to 
that of Tfr2-ECD, have increased iron levels in the spleen8; there-
fore, differences in iron metabolism may have been anticipated. In 
the future, longer and more extensive pharmacological studies are 
required to conclusively address the safety profile of Tfr2-ECD.
Taken together, our findings uncovered Tfr2 as a novel 
regulator of bone mass via modulation of the BMP-p38MAPK-Wnt 
signalling axis and identified Tfr2-ECD as a promising therapeutic 
option to treat heterotopic ossification and disorders of excessive 
bone formation.
Methods
Mice. Generation of Tfr2–/– mice and Tfr2 knock-in (Tfr2-KI) mice, which lack 
only the Tfr2β isoform, were described previously8. Conditional Tfr2 knock-out 
mice were generated on the background of the Tfr2-KI mouse (129 × 1/svJ),  
thereby generating cell-type-specific Tfr2α knock-out mice that also lack Tfr2β 
globally. Liver-specific Tfr2-knock-out (LCKO) mice were generated using 
albumin-Cre (sv129 background). To delete Tfr2α in osteoblast precursors, the 
doxycycline-repressible osterix-Cre (Osx-cre) was used61. Breeding pairs and mice 
up to the age of 5 weeks were kept on doxycycline (0.5 g/l). For the deletion of 
Tfr2α in mature osteoclasts, the cathepsin K Cre (Ctsk-cre) was used62. Lysozyme 
M Cre (Lysm-cre) was used for deletion of Tfr2 in early osteoclasts63. Tfr2f/f;Osx-
cre, Tfr2f/f;Lysm-cre, and Tfr2f/f;Ctsk-cre mice were generated on a mixed sv129/
C57BL/6 background. Littermates were used as controls.
To obtain Tfr2-deficient mice with an overproduction of human sclerostin, 
Tfr2–/– mice were crossed with Dmp1-SOST transgenic mice to obtain Tfr2–/–; 
Dmp1-SOST+/tg mice64. The production of ferroportin knock-in mice with a point 
mutation (C326S) and Hfe knock-out mice were described previously26,27. All mice 
were routinely genotyped using standard PCR protocols.
In vivo experiments. All animal procedures were approved by the institutional 
animal care committee TU Dresden and the Landesdirektion Sachsen. All  
mice were fed a standard diet with water ad libitum and were kept in groups  
of five animals per cage. Mice were exposed to a 12 h light/dark cycle and an  
air-conditioned room at 23 °C (not specific-pathogen free). Enrichment was 
provided in the form of cardboard houses and bedding material. Mice were 
randomly assigned to treatment groups, and the subsequent analyses were 
performed in a blinded fashion.
Bone phenotyping. Male and female Tfr2–/– and wild-type mice at 10–12 weeks 
of age were used. For the characterization of Tfr2–/– mice, older mice (6 and 
12 months) were also used. Male Tfr2f/f;Osx-cre and Tfr2f/f;Ctsk-cre and the 
corresponding cre-negative littermate controls were killed at 10–12 weeks of age 
for bone phenotype analysis.
Ovariectomy. Female 11- to 14-week-old WT or Tfr2–/– mice were bilaterally 
ovariectomized or sham operated. After 4 weeks, mice were killed for further 
analyses. Each group consisted of 5–10 mice.
Iron-rich diet. WT animals received a 2%-iron-enriched standard diet from 
weaning (14 days old) until euthanisation (8 weeks of treatment). There were four 
or five mice per group.
Iron-free diet. Male Tfr2–/– and WT mice received an iron-free diet (Envigo, 
Italy) from weaning until 10 weeks of age. Control mice received a standard diet 
containing 0.2 g iron/kg (GLOBAL DIET 2018, Envigo, Italy). There were nine 
mice per group.
Iron chelation. Ten-week-old male Tfr2–/– and WT mice received daily intraperi-
toneal injections of 250 mg/kg deferoxamine (Sigma, Germany, dissolved in PBS) 
or PBS for three weeks. This experiment was performed two independent times 
with 3–5 mice.
Full bone marrow transplantation. Bone marrow cells were isolated from 12-week-
old male Tfr2–/– mice or WT controls. Two million cells were transplanted into 
lethally irradiated (8 Gy) male WT or Tfr2–/– mice via retro-orbital venous plexus 
injection. Engraftment efficiency was monitored every four weeks using flow 
cytometry. After 16 weeks, mice were sacrificed for bone analyses. This experiment 
was performed twice with 7–12 mice per group.
Anisomycin treatment. Female 11-week-old WT and Tfr2–/– mice were treated with 
5 mg/kg anisomycin (intraperitoneally) 3× /week for three weeks. This experiment 
was performed twice with five mice per group.
Heterotopic ossification (HO). The HO model was performed according to 
Wosczyna et al.32. Briefly, 2.5 µ l of 1 mg/ml recombinant BMP-2 (ThermoFisher) 
or 2.5 µ l of 1 mg/ml Tfr2-ECD was mixed with 47.5 µ l Matrigel (BD Bioscience) on 
ice. For the local combination treatment, 2.5 µ l BMP-2 was mixed with 2.5 µ l Tfr2-
ECD and 45 µ l Matrigel. The Matrigel mixtures were injected into the midbelly of 
the tibialis anterior muscle of 10-week-old female WT and Tfr2-deficient mice. 
Some mice were treated daily with palovarotene through oral gavage using a 
previously published protocol58. Palovarotene (Hycultec) was dissolved in DMSO 
and diluted 1:4 with corn oil. Mice received palovarotene at a dose of 100 µ g/ 
mouse for the first 5 d and 50 µ g/mouse for the remainder of the experiment  
(days 6–14). Two weeks after BMP-2 injection, the legs were harvested for analysis. 
This experiment was performed three times with 3–11 mice per group.
To analyse the chondrogenic phase of HO, we performed the experiment as 
described above, but terminating on day 8. This experiment was performed once 
with four to six mice per group.
For systemic Tfr2-ECD treatment, WT mice were treated every other day  
with Tfr2-ECD intraperitoneally for two weeks. Mice received 250 µ g Tfr2-ECD 
(10 mg/kg body weight) per injection for the first 10 d after BMP-2/Matrigel injection 
into the muscle and 125 µ g per injection (5 mg/kg body weight) for the remaining 
time. This experiment was performed once with eight to ten mice per group.
Drop-weight HO. This experiment was performed according to Liu et al.65 with 
minor modifications. Female 10- to 12-week-old WT mice were anaesthetized 
and placed on a ridge of a plastic container over which the right leg was bent so 
the femur was lying horizontally. Mice received an injection of 1 µ g BMP-2 mixed 
in 50 µ l Matrigel. Afterwards, a stainless-steel ball of 16 g (16 mm diameter) was 
dropped from a distance of 80 cm height onto the quadriceps muscle. Mice either 
received a single dose of 1 µ g Tfr2-ECD, which was co-injected with the BMP-2/
Matrigel mixture, or palovarotene (Hycultec), which was administered daily by oral 
gavage. Palovarotene was dissolved in DMSO and diluted 1:4 with corn oil. Mice 
received palovarotene at a dose of 100 µ g/mouse for the first 5 d and 50 µ g/mouse 
for the remainder of the experiment (days 6–21). One group of mice received 
ibuprofen via their drinking water at a dose of 100 mg/ml, which was changed 
every other day66. Mice received methimazole (200 mg/kg) to reduce pain for the 
entire duration of the experiment. This experiment was performed twice with six 
mice per group.
Micro-CT, bone micromineralization density, and biomechanical testing. Bone 
microarchitecture was analysed using the vivaCT40 (Scanco Medical, Switzerland). 
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The femur and the fourth lumbar vertebra were imaged at a resolution of  
10.5 µ m with X-ray energy of 70 kVp, 114 mA, and an integration time of 200 ms. 
The trabecular bone in the femur was assessed in the metaphysis 20 slices  
below the growth plate using 150 slices. In the vertebral bone, 150 slices were 
measured between both growth plates. The cortical bone was determined in  
the femoral midshaft (150 slices). Predefined scripts from Scanco were used for  
the evaluation.
Bone micromineralization densities were determined using quantitative back-
scattered electron-scanning electron microscopy (qBSE-SEM). Fourth lumbar 
vertebrae (L4) fixed in neutral buffered formalin from 12-week-old male mice were 
embedded in methacrylate. Longitudinal block faces were cut through specimens, 
which were then polished and coated with 25 nm of carbon using a high-resolution 
sputter coater (Agar Scientific Stanstead UK). Samples were imaged using 
backscattered electrons at 20 kV, 0.4 nA, and a working distance of 17 mm with 
a Tescan VEGA3 XMU (Tescan, Brno, Czech Republic) equipped with a Deben 
24 mm four-quadrant backscatter detector (Deben, Bury St. Edmunds, UK). 
Bone mineralization densities were determined by comparison to halogenated 
dimethacrylate standards, and an eight-interval pseudocolor scheme was used to 
represent the graduations of micromineralization, as described previously67.
Three-point bending of the femur was conducted to assess bone strength. 
The femurs were stored in 70% ethanol and rehydrated in PBS prior to testing. 
Mechanical testing was performed using the zwickiLine (Zwick, Germany). Load 
was applied to the anterior side of the femoral shaft to measure the maximum load 
at failure (Fmax, N).
Bone histomorphometry. Mice were injected with 20 mg/kg calcein (Sigma) 5 d 
and 2 d before euthanisation. Dynamic bone histomorphometry was performed 
as described previously68. Briefly, the third lumbar vertebra and tibia were fixed in 
4% PBS-buffered paraformaldehyde and dehydrated in an ascending ethanol series. 
Subsequently, bones were embedded in methacrylate and cut into 7-µ m sections 
to assess the fluorescent calcein labels. Unstained sections were analysed using 
fluorescence microscopy to determine the mineralized surface/bone surface  
(MS/BS), the mineral apposition rate (MAR), and the bone formation rate/bone 
surface (BFR/BS), as well as the bone volume/total volume (BV/TV), trabecular 
number (Tb.N), trabecular separation (Tb.Sp), and trabecular thickness (Tb.Th).
To determine numbers of osteoclasts, the femur and fourth lumbar vertebra 
were decalcified for 1 week using Osteosoft (Merck), dehydrated, and embedded 
into paraffin. Tartrate-resistant acid phosphatase (TRAP) staining was used to 
assess the osteoclast surface per bone surface (Oc.S/BS). Bone sections were 
analysed using the Osteomeasure software (Osteometrics, USA) following 
international standards.
To assess HO using the haematoxylin and eosin staining, the calves (HO) and 
thighs (drop-weight) were decalcified, dehydrated, and embedded into paraffin. 
Limbs were cut into 2-µ m sections and stained with haematoxylin and eosin. For 
von Kossa/van Gieson and Safranin O staining, legs were not decalcified; they were 
embedded into methacrylate and cut into 4-µ m-thick sections.
Immunohistochemistry. For immunohistochemical analysis, paraffin sections 
from WT and Tfr2–/– bones were dewaxed, rehydrated, and heat retrieved of 
antigens. Endogenous peroxidase activity was blocked using 0.3% H2O2 in PBS for 
10 min at room temperature, and nonspecific binding sites were blocked using the 
blocking buffer of the VECTASTAIN Elite ABC Kit (VECTOR Laboratories) for 
45 min at room temperature. Afterwards, sections were incubated with an anti-Tfr2 
antibody (H-140, Santa Cruz), a β -catenin antibody (Sigma-Adrich, cat. no. C2206) 
or an axin-2 antibody (#ab107613, Abcam) overnight at 4 °C. Subsequently, slides 
were treated with an anti-mouse secondary antibody conjugated to biotin and 
then developed using avidin-conjugated HRP with diaminobenzidine as substrate 
(Dako). Slides were examined using a Zeiss Axio Imager M.1 microscope. 200 cells 
were counted per slide and graded according to no staining (0), weak staining (1), 
and strong staining (2).
Measurement of iron content in liver and bone. The iron concentration in the 
liver was determined using 20 mg of dried liver tissue, as previously published8. 
The iron concentration in the bone was determined using atomic absorption 
spectroscopy (PerkinElmer Analyst 800) of dried bone tissue (bone-marrow-
flushed femur and tibia), as previously published69.
Serum analysis. The bone turnover markers C-terminal telopeptide (CTX) and 
pro-collagen type I N-terminal peptide (P1NP) were measured in the serum using 
ELISAs (IDS, Germany). Serum dickkopf-1 and BMP-2 were measured using 
ELISAs from R&D Systems (Germany). Mouse sclerostin was measured with an 
ELISA from Alpco (USA). Serum ferritin and iron were measured using routine 
methods for clinical analyses on a Roche Modular PPE analyser. The transferrin 
saturation was determined using a total iron binding capacity kit from Randox.
Primary osteoclast culture. Osteoclasts were generated from the bone marrow 
of WT mice and seeded at a density of 1 × 106 cells/cm². Alpha-MEM (Biochrom, 
Germany) with 10% FCS, 1% penicillin/streptomycin, and 25 ng/ml M-CSF (all 
from Life Technologies) was used for the first 2 d of differentiation. Afterwards, 
medium was supplemented with 30 ng/ml RANKL (Life Technologies) for the 
remainder of the culture (5–7 d). RNA was isolated at various time points, and 
mature osteoclasts were used for immunofluorescence analysis.
Primary osteoblast culture. Primary murine osteoblasts were differentiated from 
the bone marrow using standard osteogenic medium in DMEM with 10% FCS, 1% 
penicillin/streptomycin (Life Technologies, Germany). RNA was isolated at various 
time points, and day 7 osteoblasts were used for immunofluorescence analysis of 
Tfr2 and the deep-sequencing analysis.
Signalling studies. Day 7–differentiated cells were treated with 50 ng/ml BMP-2, 
BMP-4 or BMP-6 for 0, 20, and 40 min and lysed in protein lysis buffer (at least two 
independent experiments with n = 3 each for each group). Anisomycin was used 
to activate MAPK signalling on day 7–differentiated osteoblasts. Cells were treated 
with 100 nM anisomycin for 20 min for subsequent protein analysis. For RNA 
isolation and detection of gene expression, cells were treated with different doses 
(10 and 100 nM) of anisomycin for 24 h (two independent experiments with n = 3 
for each group).
Overexpression. 1 µ g of the pcDNA3.1 vector containing the murine Tfr2 gene was 
transfected into 70–80% confluent cells using Fugene HD (Roche)8. An empty 
pcDNA3.1 vector was used as a control. Additionally, the overexpression vectors 
pCMV6-MAPK1 (ERK2), pCMV6-MAPK14 (p38), pCMV6-Smad1, and pCMV6-
Smad4 were purchased from Origene to overexpress the respective signalling 
proteins. The pCMV6-Entry vector was used as control. Each experiment was 
performed once with cells from four different mice.
RNA isolation, reverse transcription, and real-time PCR. RNA from cell cultures 
was isolated with the High Pure RNA Isolation Kit (Roche), and RNA from the 
bones of mice was isolated by crushing flushed bones (femur and tibia) in liquid 
nitrogen and collecting the bone powder in Trifast (Peqlab, Germany). Other 
organs were homogenized directly in Trifast using an ULTRA-TURRAX (IKA, 
Germany). 500 ng RNA was reverse transcribed using Superscript II (Invitrogen, 
Germany) and subsequently used for SYBR green–based real-time PCR using a 
standard protocol (Life Technologies). The results were calculated using the Δ Δ CT 
method and are presented in x-fold increase relative to β-actin (or GAPDH where 
indicated) mRNA levels.
Protein isolation and western blot. Cells were lysed in a buffer containing 
20 mM Tris/HCl, pH 7.4, 1% SDS, and a protease inhibitor (complete mini, 
Roche, Germany). To isolate protein from tissues, the protein fraction of the 
Trifast procedure was used and further processed according to the manufacturer’s 
protocol. The protein concentration was determined using the BCA method 
(Pierce, Germany). 20 µ g of heat-denatured protein was loaded onto a 10% gel, 
separated, and transferred onto a 0.2-μ m nitrocellulose membrane (Whatman, 
Germany). After blocking for 1 h with 5% non-fat dry milk or 2% BSA in Tris-
buffered saline with 1% Tween-20 (TBS-T), membranes were incubated with 
primary antibodies to signalling proteins (Cell Signaling) overnight and washed 
three times with TBS-T. For the detection of Tfr2, the H-140 antibody from 
Santa Cruz (Germany) was used, which detects an epitope corresponding to 
amino acids 531–670. Other antibodies used were: lamin A/C (#sc-20681, Santa 
Cruz), connexin-43 (#3512, Cell Signaling), tubulin (#2146, Cell Signaling), 
and GAPDH (#5G4, HytestH). Thereafter, membranes were incubated with the 
appropriate HRP-conjugated secondary antibodies for 1 h at room temperature. 
Finally, membranes were washed with TBS-T and incubated with an ECL substrate 
(ThermoFisher Scientific). The proteins were visualized using the MF-ChemiBIS 
3.2 bioimaging system (Biostep, Germany). All unprocessed western blot images 
are shown in Supplementary Figs. 10 and 11.
Subcellular protein fractionation. For separation of cytoplasmic, membrane, 
and nuclear protein extracts of osteoblasts, primary murine osteoblasts were 
differentiated from the bone marrow of three WT mice. At day 7, cells were 
harvested, and the subcellular protein fractions were isolated using the subcellular 
protein fractionation kit (ThermoFisher Scientific) according to manufacturer’s 
recommendation.
Immunofluorescence staining. For immunofluorescence staining, cells were 
grown on glass slides. At the desired time point, cells were fixed with 100% 
methanol for 15 min, permeabilised with 0.5% Triton X-100 for 10 min and, after 
three washes, blocked with 1% BSA in PBS for 30 min. Afterwards, cells were 
incubated with an anti-mouse Tfr2 antibody (H-140, Santa Cruz) overnight at  
4 °C. After being washed, cells were stained with an anti-mouse osterix antibody 
(sc-393325, Santa Cruz) or phalloidin at room temperature for 1 h. Subsequently, 
cells were washed and incubated for 1 h with an Alexa Fluor 488– or Alexa Fluor 
594–labelled secondary antibody (Life Technologies), washed, and stained with 
DAPI for 5 min. After being washed again, glass slides were embedded in a small 
droplet of mounting medium (Dako). Slides were examined using a Zeiss LSM 510 
confocal microscope (Zeiss EC Plan-Neofluar 40× /1.3 oil), and photographs were 
taken and processed with the Zen 2009 software.
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Coimmunoprecipitation. Human hepatoma cells (HuH7) were transfected with 
7.5 μ g of pCMV-3XFLAG-BMPR-IA  and  7.5 μ g pcDNA3-TFR2-HA or pcDNA3-
LDLR-HA using TransIT-LT1 Transfection Reagent (Mirus Bio LLC) following the 
manufacturer’s protocol. 48 h after transfection, cells were treated with 50 ng/ml 
of BMP-2 (Peprotech) for 1.5 h, where indicated. Cell lysates were incubated with 
pre-equilibrated anti-FLAG M2 affinity gel (Sigma Aldrich) at 4 °C for 2 h. Samples 
were then eluted with 50 μ l of lysis buffer containing 300 μ g/ml 3× FLAG Peptide 
(Sigma Aldrich). 10% of the total lysate was used as input (In). Immunorecognition 
was visualized using α FLAG and α HA antibodies (1:1,000, Sigma Aldrich; cat. nos. 
H9758, F7425).
Next-generation sequencing and data analysis. Total RNA was isolated from 
day 7–differentiated cells of Tfr2–/– and WT mice using Trifast. RNA quality was 
assessed using the Agilent Bioanalyzer, and total RNA with an integrity number  
≥ 9 was used. mRNA was isolated from 1 µ g total RNA using the NEBNext Poly(A) 
mRNA Magnetic Isolation Module according to the manufacturer’s instructions. 
After chemical fragmentation, samples were subjected to strand-specific RNA-
sequencing library preparation (Ultra Directional RNA Library Prep, NEB). After 
ligation of adaptors (Oligo1, 5′ -ACA CTC TTT CCC TAC ACG ACG CTC TTC 
CGA TCT-3′ ; Oligo 2, 5′ -P-GAT CGG AAG AGC ACA CGT CTG AAC TCC 
AGT CAC-3′ ), residual oligos were depleted using bead purification (XP, Beckman 
Coulter). During subsequent PCR enrichment (15 cycles) libraries were indexed 
(Primer 1: Oligo_Seq AAT GAT ACG GCG ACC ACC GAG ATC TAC ACT 
CTT TCC CTA CAC GAC GCT CTT CCG ATC T; primer 2: GTG ACT GGA 
GTT CAG ACG TGT GCT CTT CCG ATC T; primer 3: CAA GCA GAA GAC 
GGC ATA CGA GAT NNNNNN GTG ACT GGA GTT). After final purification 
(XP beads), libraries were quantified (Qubit dsDNA HS Assay Kit, Invitrogen), 
equimolarly pooled, and distributed on multiple lanes for 75-bp single-read 
sequencing on an Illumina HiSeq 2500 and an Illumina NextSeq 500.
After sequencing, FastQC (http://www.bioinformatics.babraham.ac.uk/) was 
used for basic quality control. Reads were then mapped onto the mouse genome 
(mm10) using GSNAP (version 2014-12-17) together with known splice sites 
(Ensembl v75) as support. Library diversity was assessed by investigating the 
redundancy in the mapped reads. A table with counts per gene was obtained by 
running featureCounts (v1.4.6) on the uniquely mapped reads using Ensembl v75 
gene annotations. Normalisation of the raw read counts based on the library size 
and testing for differential expression between KO and WT was performed with 
the R package DESeq2 (v1.6.3). Genes with an adjusted (Benjamini–Hochberg)  
P value < 0.05 were considered as differentially expressed.
Gene ontology analyses were performed with Cytoscape 3.2.1 and the ClueGO 
plugin. Only significantly (P < 0.05) up- or downregulated genes were fed into the 
analyses. Gene Set Enrichment Analysis (GSEA) was carried out using the Broad 
Institute GSEA software “GseaPreRanked” tool (nperm = 1,000, set_min = 5, set_
max = 500, scoring_scheme = weighted) to analyse a list of 18,106 nonredundant 
gene symbols ranked by their log2 fold-change of expression between Tfr2–/– and 
WT conditions. In total, 58 gene sets were used for the analysis, including 50 
Hallmark gene sets70, three osteoblast-specific gene sets from Park et al.71 and five 
other gene sets from Sanjuan-Pla et al.72.
Expression of the Tfr2 extracellular domain. The coding sequence of the full-
length extracellular domain (ECD, amino acids 103–798) of murine Tfr2 was 
synthesised by Genscript (Germany). Recombinant His-MBP-c3-Tfr2-ECD was 
expressed in Sf9 insect cells using the baculovirus expression system (pOCC211-
Tfr2-ECD). Culture supernatant (5 litres) was harvested, filtered, and loaded on 
a HisTrap column, and after extensive wash with PBS, the Tfr2-ECD protein was 
eluted using PBS with 250 mM imidazole. The yield in the first protein production 
was 40 mg Tfr2-ECD, and the yield in the second protein production was 46 mg 
Tfr2-ECD. Presence of Tfr2 was analysed using Coomassie staining of SDS–PAGE 
with reducing conditions and western blot.
Experiments were repeated with a commercially produced Tfr2-ECD from 
Cusabio. This commercial fragment also contained the entire ECD (amino acids 
103–798), and was dissolved in PBS only.
Surface plasmon resonance binding and kinetic analysis. Interactions of the 
Tfr2-ECD and holo-Tf, BMP ligands (BMP-2, BMP-4, BMP-6, and BMP-7, R&D 
Systems) and BMP receptors (BMPR-IA, BMPR-II, R&D Systems) were analysed 
using a Biacore T100 instrument (GE Healthcare). Tfr2-ECD, BMP-2, and BMP-4 
were immobilised onto Series S Sensor Chips C1 (GE Healthcare) via its amine 
groups at 25 °C. The carboxyl groups on the chip surface were activated for 
7 min with a mixture containing 196 mM 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide hydrochloride and 50 mM N-hydroxysuccinimide at a flow rate  
of 10 µ l/min. Next, 5 µ g/ml of Tfr2-ECD diluted in sodium acetate buffer  
(pH 4.5) or 2 µ g/ml BMP-2 or BMP-4 was injected at a flow rate of 5 µ l/min until 
immobilization levels of approximately 200 RU (Tfr2-ECD) or 100 RU (BMP-2 
and BMP-4) were achieved. Unreacted groups were deactivated via injection of 
1 M ethanolamine-HCl, pH 8.5 (7 min, 10 µ l/min). A reference surface was created 
according to the same protocol but omitting the Tfr2 injection.
The binding analysis was performed at 37 °C at a flow rate of 30 µ l/min. 
Each analyte was diluted in running buffer (HBS-P (pH 7.4), 150 mM NaCl, 
supplemented with 50 nM FeCl3). In some experiments, 500 mM NaCl was 
used to reduce potential nonspecific binding. BMP ligands were used at the 
indicated concentrations (0–50 nM). BMP receptors were used at a concentration 
of 2–200 nM, holo-Tf at 2.5–100 µ M, and Tfr2-ECD at 10–5,000 nM. In some 
experiments, BMP-2–BMPR-IA and BMP-2–holo-Tf were injected at the same 
time. Concentration-dependent binding of holo-Tf was performed without 
intermediate regeneration.
For binding analysis, an injection of analyte for 240 s or 300 s over a Tfr2-ECD 
surface was followed by a 1,000-s dissociation. The values of the binding levels 
were recorded from referenced signals 10 s before the end of the injection relative 
to baseline response, then emended for the respective molecular weight. After 
dissociation for 1,000 s, the chip surface was regenerated for 60 s with 5 M NaCl, 
50 mM NaOH in HBS-P, followed by a 1,000-s stabilization.
Single-cycle kinetics with five sequential analyte injections was carried out with 
a sensitivity-enhanced Biacore T200 (GE Healthcare) to determine the Kd range of 
Holo-Tf/Tfr2 and the dissociation rates, koff (complex stabilities), for Tfr2 binding to 
BMP-2 and BMP-4 surfaces. The kinetic fitting was performed by global fitting using 
the 1:1 Langmuir binding model (A + B = AB). Steady-state analyses were conducted 
to determine the affinities (Kd). Therefore, a 1:1 interaction of Tfr2 with BMP-2 
or BMP-4 was assumed by fitting the measured binding responses at equilibrium 
against the concentration. To achieve a robust fit and the typical curvature of the 
plot, a wide range of Tfr2 concentrations was analysed (10–5,000 nM). Binding and 
kinetic parameters were evaluated with Biacore T200 evaluation software 3.1.
BMP-2 competitive ELISA. We used the Duo Set BMP-2 ELISA kit from R&D 
Systems for BMP-2 competitive ELISA assays. After coating the plate with the 
BMP-2 capture antibody overnight, 1.5 ng/ml BMP-2 was added with increasing 
concentrations of the Tfr2-ECD or the BMPR-IA (positive control, R&D Systems). 
After 1 h of incubation at room temperature RT and extensive washing, the 
detection antibody was added according to the manufacturer’s protocol, and the 
amount of BMP-2 was quantified. This experiment was performed at least three 
independent times.
Statistical analysis. Data are presented as mean ± standard deviation (SD). Graphs 
and statistics were prepared using GraphPad Prism 6.0 software. Normality of 
data was determined using the Kolmogorov–Smirnov test. In cases where data 
were normally distributed, statistical evaluations of two group comparisons 
were performed using a two-sided Student’s t test. One-way analysis of variance 
(ANOVA) was used for experiments with more than two groups. Two-way 
ANOVA with Bonferroni post hoc tests were used for analysing genotype and 
treatment effects. If data were not normally distributed, the Mann–Whitney 
test and the Wilcoxon signed rank test were used for data analysis. Frequency 
distributions of micromineralization densities from qBSE-SEM grey-scale images 
were compared using the Kolmogorov–Smirnov test67.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Data availability
All data sets generated during the current study are available from the 
corresponding author upon reasonable request. 
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?    Experimental design
1.   Sample size
Describe how sample size was determined. Sample sizes were chosen based on experience from previous studies to balance 
the ability to measure significant differences while reducing the number of animals 
used. Sample sizes were adjusted in some rodent studies when greater biological 
variability was expected due to use of a mixed background strain. 
For gene and protein expression level analysis by qPCR and Western Blot as well as 
ELISA, combining a technical duplicate (intra-sample variability) with at least a 
biological triplicate (inter-experiment variability) was applied to detect a pre-
specified effect size.
2.   Data exclusions
Describe any data exclusions. No data were excluded from successfully performed experiments.
3.   Replication
Describe whether the experimental findings were 
reliably reproduced.
All attempts at replication were successful. Key experiments were performed at 
least two independent times and were replicated by two different investigators. 
For some findings, several methods have been used to verify the results. 
4.   Randomization
Describe how samples/organisms/participants were 
allocated into experimental groups.
The animals were randomly assigned to experimental groups.
5.   Blinding
Describe whether the investigators were blinded to 
group allocation during data collection and/or analysis.
Investigators were not blinded for group allocation for practical reasons. However, 
during data collection and analyses, the experimentors were blinded. 
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
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6.   Statistical parameters 
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the 
Methods section if additional space is needed). 
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same 
sample was measured repeatedly
A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one- or two-sided (note: only common tests should be described solely by name; more 
complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted
A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
?   Software
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7. Software
Describe the software used to analyze the data in this 
study. 
Microsoft Office Excel and Graphpad Prism 6.0 were used to perform statistical 
analyses. Gene ontology analyses of next generation sequencing were performed 
with Cytoscape 3.2.1 and the ClueGO plugin.
For manuscripts utilizing custom algorithms or software that are central to the paper but not yet described in the published literature, software must be made 
available to editors and reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub). Nature Methods guidance for 
providing algorithms and software for publication provides further information on this topic.
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8.   Materials availability
Indicate whether there are restrictions on availability of 
unique materials or if these materials are only available 
for distribution by a for-profit company.
All materials in this study are either available from authors or from companies 
listed in Method section.
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9.   Antibodies
Describe the antibodies used and how they were validated 
for use in the system under study (i.e. assay and species).
The following primary antibodies were used for western blot and 
immunhistological staining: 
ß-actin (rabbit): Cell Signaling, cat# 4970, clone 13E5, dilution 1:2000 
Axin-2 (rabbit): Abcam, cat#ab107613, dilution 1:500 
ß-catenin (rabbit) for WB: Cell Signaling, cat# 9582, clone 6B3, dilution 1:1000 
ß-catenin for IHC (rabbit): Sigma-Aldrich, cat# C2206, dilution 1:2000 
ß-tubulin (rabbit): Cell Signaling, cat#2146, dilution 1:1000 
Connexin-43 (rabbit): Cell Signaling, #3512, dilution 1:1000 
Erk (p44/42 MAPKinase) (rabbit): Cell Signaling, cat# 4695, clone 137F5, dilution 
1:1000  
GAPDH (rabbit): Hytest, cat#5G4, dilution 1:1000 
Lamin A/C (rabbit): Santa Cruz, cat# sc-20681; dilution 1:1000 
Osterix (mouse): Santa Cruz, cat# sc-393325; dilution 1:500 
phospho-Erk (rabbit): Cell Signaling, cat# 4370,  clone D13.14.4E, dilution 1:1000 
p38 (rabbit): Cell Signaling, cat# 9212,dilution: 1:1000 
phospho-p38 (rabbit): Cell Signaling, cat# 4511, clone D3F9, dilution 1:500 
phospho-Smad1/5 (rabbit): Cell Signaling, cat# 9516, clone 13E5, dilution 1:1000 
phospho-Smad 1/5/8 (rabbit): Cell Signaling, cat# 13820P; clone D5B10, dilution 
1:1000 
Smad5 (rabbit): Cell Signaling, cat# 9517, dilution 1:1000 
Tfr2 (H-140) (rabbit): Santa Cruz, cat# sc-48747, dilution 1:1000 
HA (HA-7)(mouse): Sigma Aldrich, cat# H9658, dilution 1:1000 
FLAG (rabbit): Sigma Aldrich, cat# F7425, dilution 1:1000 
 
Secondary antibodies for WB 
anti-rabbit IgG, Cell Signaling, cat# 7074, dilution 1:2000 
anti-mouse IgG, Sigma Aldrich, cat# A9044, dilution 1:5000 
Secondary antibodies for IHC 
Alexa Fluor 594 F(ab) 2 fragment goat anti-rabbit IgG (H+L), Invitrogen, cat# 
A11072, dilution 1:1000 
10. Eukaryotic cell lines
a.  State the source of each eukaryotic cell line used. Huh-7 Human Hepatoma cell line
b.  Describe the method of cell line authentication used. Gene expression response of hepatic genes upon specific stimuli 
c.  Report whether the cell lines were tested for 
mycoplasma contamination.
Mycoplasma test was negative
d.  If any of the cell lines used are listed in the database 
of commonly misidentified cell lines maintained by 
ICLAC, provide a scientific rationale for their use.
No commonly misidentified cell lines were used.
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11. Description of research animals
Provide details on animals and/or animal-derived 
materials used in the study.
Tfr2-/- mice were on a 129/sv background. Tfr2fl/fl; CtskCre, Tfr2fl/fl; OsxCre mice, 
Tfr2fl/fl; LysmCre mice as well as Tfr2-/-; Dmp1-SOST-tg mice were on a mixed 
sv129/C57BL/6 background. Male and female mice were used at 10 -12 weeks of 
age. For some experiments, older mice aged 6 -12 months were used. 
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12. Description of human research participants
Describe the covariate-relevant population 
characteristics of the human research participants.
No human data were used in this study. 
